SINOPHARM GROUP CO (SHTDY) News

Zhitong HK Stock Investment Log | September 10

HK Stock Investment Log | September 10, 2026

Zhitong Finance00:00

Sinopharm Group Stock Slips 2.1% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Sinopharm Group Co. Ltd. slid 2.1% to 15.70 Hong Kong dollars on what proved to be an all-

Dow JonesSep 9 16:32

Mainland China's 2026 National Reimbursement Drug List is expected to be released in November.

According to CCTV, the National Healthcare Security Administration organized on-site price negotiations for the 2026 National Reimbursement Drug List (NRDL) from September 5 to 8. Over 100 domestic and foreign enterprises participated in person, with 124 drugs not currently on the list shortlisted for negotiation. Innovative medicines in key areas of public concern, including oncology, rare diseases, chronic conditions, and pediatric treatments, were included in the negotiations and are expected to be added to the reimbursement list. Concurrently, adjustments to the innovative drug catalog for commercial health insurance were carried out, with 12 drugs undergoing on-site price consultations. The 2026 National Reimbursement Drug List and the Commercial Insurance Innovative Drug Catalog are scheduled for release in November this year, taking effect on January 1, 2027.

AASTOCKSSep 9 14:19

CLSA: China’s Innovative Drug Sector Returns to Alpha Dominance; Macro Volatility May Present Buying Opportunities

A report by CLSA indicates that China’s innovative drug sector is returning to a market driven primarily by company fundamentals and stock-specific alpha, with the influence of company-specific fundamentals—particularly business development (BD) and Phase III clinical progress—rising relative to macro factors (beta). Attribution analysis by the bank shows that the explanatory power of fundamentals for pharmaceutical stock price movements reached 82.7% from 2015 to 2021, fell to approximately 32.7% from 2021 to 2024, and has rebounded to over 54% since 2025, partly supported by BD developments and key overseas Phase III trials. The bank expects that, as market sentiment toward

AASTOCKSSep 9 12:08

Sinopharm Group Stock Climbs 1.3% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Sinopharm Group Co. Ltd. advanced 1.3% to 16.03 Hong Kong dollars on what proved to be an all-

Dow JonesSep 8 16:33

Sinopharm Group Stock Rallies 0.9% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Sinopharm Group Co. Ltd. inched 0.9% higher to 15.83 Hong Kong dollars on what proved to be

Dow JonesSep 7 16:33

Sinopharm Group (1099.HK): Improved Operations in Medical Devices Segment; Bullish on Steady Earnings Release

Key TakeawayOn August 24, the company released its interim results for 2026.

China Securities Co., Ltd.Sep 7 16:26

Sinopharm Group Stock Advances 1.5% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Sinopharm Group Co. Ltd. advanced 1.5% to 15.69 Hong Kong dollars on what proved to be an all-

Dow JonesSep 4 16:33

Sinopharm Group Stock Slides 2.7% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Sinopharm Group Co. Ltd. slid 2.7% to 15.50 Hong Kong dollars on what proved to be an all-

Dow JonesAug 31 16:33

Sinopharm Group (01099.HK): Sinopharm Accord reported a net profit of RMB 606 million in the first half of the year, a year-on-year decrease of 8.97%.

Gelonghui, August 28 | Sinopharm Group (01099.HK) announced that Sinopharm Accord (000028.SZ) released its 2026 semi-annual report, reporting total operating revenue of RMB 36.266 billion, a year-on-year decrease of 1.44%; net profit attributable to shareholders of the listed company was RMB 606 million, a year-on-year decrease of 8.97%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB 599 million, a year-on-year decrease of 6.84%; basic earnings per share was RMB 0.99.

Gelonghui FinanceAug 28 18:20

Sinopharm Subsidiary Sinopharm Accord Posts Lower Interim Profit and Negative Cash Flow

TipRanksAug 28 18:18

SINOPHARM: ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE SIX MONTHS ENDED 30 JUNE 2026

HKEXAug 28 17:43

Sinopharm Group Stock Slips 1.9% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Sinopharm Group Co. Ltd. shed 1.9% to 15.81 Hong Kong dollars on what proved to be an all-

Dow JonesAug 27 16:32

Sinopharm Group Co (SHTDF) Gets a Buy From Citi

TipRanksAug 27 08:28

Sinopharm Group Stock Rallies 1.1% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Sinopharm Group Co. Ltd. advanced 1.1% to 16.12 Hong Kong dollars on what proved to be an all-

Dow JonesAug 26 16:33

Goldman Sachs: Sinopharm Group (01099.HK) Q2 results meet expectations; target price cut to HK$18.46

Goldman Sachs released a report stating that Sinopharm Group (01099.HK) saw its second-quarter sales decline by 1.6% year-on-year to RMB 142.4 billion, broadly in line with expectations. During the period, gross margin came under pressure, falling to 7.05% from 7.46% in the same period last year, primarily due to the continued advancement of centralized volume-based procurement (VBP) for pharmaceuticals and medical devices, healthcare cost containment measures, and structural pricing headwinds. However, stringent cost controls effectively alleviated profit pressures, with selling and administrative expenses decreasing by 6% year-on-year and financing costs dropping to 0.44% of sales. This drove net profit to decline by only 1% year-on-year to RMB 2.0 billion, meeting Goldman Sachs' expectations. Management stated that in May

AASTOCKSAug 26 14:35

Sinopharm Group Co (SHTDF) Gets a Buy From CICC

TipRanksAug 26 13:18

CLSA lowers target price for Sinopharm (01099.HK) to HK$21.1, reaffirms "Outperform" rating

In a research report, CLSA noted that Sinopharm Group (01099.HK) saw its first-half revenue decline by 1.1% year-on-year and net profit decrease by 1.8% year-on-year, primarily due to centralized drug procurement and a tightening regulatory environment. The report highlighted that Sinopharm’s management remains optimistic about the second half of the year, expecting a recovery in revenue growth, gradual improvement in gross margins, and accelerated collection of accounts receivable as the group continues to implement operational efficiency measures. CLSA lowered its revenue forecasts for Sinopharm for 2026–2028 by 2.7% to 4.7% and reduced its net profit estimates by 1.2% to 2.3%. The target price was cut from HK$25 to HK$21.1.

AASTOCKSAug 26 12:07

Sinopharm Holdings (01099.HK): Results in line with expectations; the retail segment continues to grow rapidly.

Performance Review – 1H26: Results in Line with Our Expectations The company reported first-half 2026 revenue of RMB 282.80 billion, down 1.13% year over year, and net profit of RMB 5.18 billion, down 2.

CICCAug 25 19:22

Sinopharm Group (01099.HK) fell 3.6% after Citi cut its target price to HK$20.4.

Sinopharm Group (01099.HK) opened lower by 2.02% today, hitting a low of HK$15.67. It is currently trading at HK$15.75, down 3.55%, with turnover of 6.3919 million shares and traded value of HK$101 million. Citi issued a report stating that Sinopharm Group’s first-half results fell short of expectations, with revenue of RMB 282.8 billion, a year-on-year decline of 1.1%, missing the bank’s and market consensus estimates by 2.3% and 2.1%, respectively. Net profit stood at RMB 3.4 billion, down 1.8% year-on-year, falling short of the bank’s and market expectations by 9.9% and 7.1%, respectively. The underperformance was primarily due to pressure on gross margins, which contracted by 37 basis points year-on-year during the period.

AASTOCKSAug 25 14:22